Naringenin chalcone

Naringenin chalcone is an orally active intermediate in flavonol biosynthesis. Naringenin chalcone induces Apoptosis. Naringenin chalcone inhibits the production of MCP-1 and NO. Naringenin chalcone exhibits anticancer activity against glioblastoma. Naringenin chalcone has anti-inflammatory and anti-allergic properties^{[1][2][3][4][5][6]}. In Vitro:Naringenin chalcone (25-200 μM; 24 h) inhibits the production of MCP-1, TNF-α, and NO in lipopolysaccharide (LPS)-stimulated RAW 264 macrophages in a dose-dependent manner^[1].
Naringenin chalcone (0-100 μM; 48 h) induces apoptosis in U87MG human glioblastoma cells in a dose-dependent manner, manifested by cell morphological changes such as cell shrinkage and apoptotic body formation^[3].
Naringenin chalcone (25-100 μM; replenished every 2 days) significantly increases adiponectin mRNA levels and protein secretion in 3T3-L1 adipocytes^[4].
In Vivo:Naringenin chalcone (0.8 mg/kg; p.o.; daily) reduces eosinophilic airway inflammation, airway hyperresponsiveness, suppressed Th2 cytokine production by splenic CD4⁺ T cells, and slightly reduced mucus overproduction in allergic asthmatic BALB/c mice^[2].
Naringenin chalcone (5-80 mg/kg; 24 days) reduced tumor volume and tumor weight in U87MG human glioblastoma xenograft Balb/c nude mice^[3].
Naringenin chalcone (p.o.) increases plasma adiponectin levels in diabetic mice^[4].
Naringenin chalcone (0.02%; i.v.) inhibits the anaphylactic response to IgE-mediated passive cutaneous anaphylaxis in CD-1 mice^[5].
Naringenin chalcone (20 mg/kg; p.o.; once) resultes in the detection of naringenin chalcone -2'-O-β-D-glucuronide in the plasma of male Sprague-Dawley rats^[6].